|
Index of reports
> Cases resulting in other serious reactions (13)
Below is the selection of adverse event reports related to MS Contin (Morphine) that includes cases resulting in other serious reactions.
Adverse event in male receiving MS Contin (Morphine)
Reported by a individual with unspecified qualification on 2007-10-12
Patient: male
Adverse reactions / side effects: Confusional State, Paranoia, Hallucination, Delusion, Aggression
Suspect drug(s):
Desyrel
Dosage: 75 mg, daily
Indication: Drug USE FOR Unknown Indication
Morphine Sulfate
Dosage: 5 mg, prn
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
MS Contin
Dosage: unk, unk
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Adverse event in 73 year old male receiving MS Contin (Morphine)
Reported by a individual with unspecified qualification on 2007-07-19
Patient: 73 year old male
Adverse reactions / side effects: Metastatic Neoplasm, Malaise, Restlessness, Anorexia, Blindness, Antisocial Behaviour
Adverse event resulted in: death, disablity
Suspect drug(s):
MS Contin (Morphine)
Adverse event in 45 year old male receiving MS Contin (Morphine)
Reported by a physician from United States on 2007-07-09
Patient: 45 year old male, weighing 79.4 kg (174.7 pounds)
Adverse reactions / side effects: Mydriasis, Visual Disturbance, Memory Impairment, Convulsion, Tremor
Suspect drug(s):
MS Contin
Dosage: see image
Administration route: Oral
Indication: Back Pain
Start date: 2004-01-01
End date: 2007-04-01
MS Contin
Dosage: see image
Administration route: Oral
Indication: Back Pain
Start date: 2004-01-01
End date: 2007-04-01
Oxycontin
Dosage: 80 mg, bid, oral
Administration route: Oral
Indication: Back Pain
Start date: 2004-01-01
End date: 2007-04-01
Restoril
Dosage: 60 mg, qd prn, oral
Administration route: Oral
Indication: Insomnia
Start date: 2005-01-01
Roxicodone
Dosage: 30 mg, qid, oral
Administration route: Oral
Indication: Back Pain
Start date: 2004-01-01
End date: 2007-04-01
Adverse event in 42 year old female receiving MS Contin (Morphine)
Reported by a physician from United States on 2007-06-27
Patient: 42 year old female
Adverse reactions / side effects: Confusional State, Dyspnoea, Neuropathy Peripheral, Abnormal Behaviour, Drug Interaction, Mood Swings, Disease Progression
Suspect drug(s):
MS Contin
Dosage: 15 mg qd po
Administration route: Oral
Indication: Complex Regional Pain Syndrome
Start date: 2006-10-01
Namenda
Dosage: 10 mg bid po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-01-01
End date: 2006-12-13
Namenda
Dosage: 5 mg bid po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-12-14
End date: 2006-12-20
Namenda
Dosage: 5 mg qd po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-11-01
End date: 2006-01-01
Namenda
Dosage: 5 mg bid po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-01-01
End date: 2006-01-01
Namenda
Dosage: 15 mg qd po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-01-01
End date: 2006-01-01
Other drugs received by patient: Warfarin Sodium; Crestor; Darvocet; Spiriva; Levoxyl; Oxygen
Adverse event in female receiving MS Contin (Morphine)
Reported by a individual with unspecified qualification on 2007-05-23
Patient: female
Adverse reactions / side effects: Lymphadenopathy, Pruritus, Urticaria, Scleroderma, Pharyngeal Oedema, Connective Tissue Disorder, Abscess Limb, Cutaneous Lupus Erythematosus, Ligament Injury, Pelvic Mass, Pain in Extremity, Osteomyelitis Chronic, Osteitis, Vertebral Injury, Throat Irritation, Dehydration, Lymphoma, Pharmaceutical Product Complaint, Therapeutic Agent Toxicity, Pain, Impaired Work Ability, Constipation, Nasal Oedema, Road Traffic Accident, Adrenal Insufficiency, Myocardial Infarction, Medication Residue, Dyspnoea, Joint Dislocation, Uterine Cancer, Lung Disorder, Alopecia, Memory Impairment, Syncope Vasovagal, Immune System Disorder
Adverse event resulted in: hospitalization, disablity
Suspect drug(s):
MS Contin
Dosage: 60 mg, unk
Indication: Systemic Lupus Erythematosus
MS Contin
Dosage: 100 mg, bid prn
Adverse event in female receiving MS Contin (Morphine)
Reported by a individual with unspecified qualification on 2007-05-18
Patient: female
Adverse reactions / side effects: Pruritus, Lymphadenopathy, Urticaria, Scleroderma, Pharyngeal Oedema, Connective Tissue Disorder, Abscess Limb, Cutaneous Lupus Erythematosus, Pelvic Mass, Ligament Injury, Pain in Extremity, Osteomyelitis Chronic, Osteitis, Vertebral Injury, Throat Irritation, Dehydration, Pharmaceutical Product Complaint, Lymphoma, Pain, Impaired Work Ability, Therapeutic Agent Toxicity, Constipation, Nasal Oedema, Road Traffic Accident, Adrenal Insufficiency, Myocardial Infarction, Medication Residue, Dyspnoea, Joint Dislocation, Uterine Cancer, Lung Disorder, Alopecia, Memory Impairment, Immune System Disorder, Syncope Vasovagal
Adverse event resulted in: hospitalization, disablity
Suspect drug(s):
MS Contin (Morphine)
Adverse event in male receiving MS Contin (Morphine)
Reported by a individual with unspecified qualification on 2007-05-09
Patient: male
Adverse reactions / side effects: Overdose, Unevaluable Event
Adverse event resulted in: hospitalization
Suspect drug(s):
MS Contin
Indication: Drug USE FOR Unknown Indication
Narcan
Indication: Drug USE FOR Unknown Indication
Adverse event in 42 year old female receiving MS Contin (Morphine)
Reported by a physician from United States on 2007-05-09
Patient: 42 year old female
Adverse reactions / side effects: Back Pain, Confusional State, Dyspnoea, Abnormal Behaviour, Condition Aggravated, Drug Interaction, Cognitive Disorder, Amnesia, Complex Regional Pain Syndrome, Neuropathy Peripheral, Mood Swings
Suspect drug(s):
MS Contin
Dosage: 15 mg qd po
Administration route: Oral
Indication: Complex Regional Pain Syndrome
Start date: 2006-10-01
Namenda
Dosage: 10 mg bid po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-01-01
End date: 2006-12-13
Namenda
Dosage: 5 mg bid po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-12-14
End date: 2006-12-20
Namenda
Dosage: 5 mg qd po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-11-01
End date: 2006-01-01
Namenda
Dosage: 5 mg bid po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-01-01
End date: 2006-01-01
Namenda
Dosage: 15 mg qd po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-01-01
End date: 2006-01-01
Other drugs received by patient: Warfarin Sodium; Crestor; Darvocet; Spiriva; Levoxyl; Oxygen
Adverse event in 80 year old male receiving MS Contin (Morphine)
Reported by a pharmacist from Japan on 2007-04-04
Patient: 80 year old male
Adverse reactions / side effects: Drug Interaction, Hallucination
Suspect drug(s):
MS Contin (Morphine)
Other drugs received by patient possibly interacting with the suspect drug:
Halcion
Dosage: daily dose:.375mg
Administration route: Oral
Adverse event in 42 year old female receiving MS Contin (Morphine)
Reported by a physician from United States on 2007-03-13
Patient: 42 year old female
Adverse reactions / side effects: Back Pain, Confusional State, Dyspnoea, Abnormal Behaviour, Drug Interaction, Amnesia, Disease Progression, Hyperaesthesia, Neuropathy Peripheral, Mood Swings
Suspect drug(s):
MS Contin
Dosage: 15 mg qd po
Administration route: Oral
Indication: Complex Regional Pain Syndrome
Start date: 2006-10-01
Namenda
Dosage: 10 mg bid po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-01-01
End date: 2006-12-13
Namenda
Dosage: 5 mg bid po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-12-14
End date: 2006-12-20
Namenda
Dosage: 5 mg qd po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-11-01
End date: 2006-01-01
Namenda
Dosage: 5 mg bid po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-01-01
End date: 2006-01-01
Namenda
Dosage: 15 mg qd po
Administration route: Oral
Indication: Neuropathy Peripheral
Start date: 2006-01-01
End date: 2006-01-01
Other drugs received by patient: Warfarin Sodium; Crestor; Darvocet (Propoxyphene / Acetaminophen); Spiriva; Levoxyl; Oxygen
Adverse event in 47 year old female receiving MS Contin (Morphine)
Reported by a health professional (non-physician/pharmacist) from United States on 2007-02-21
Patient: 47 year old female, weighing 52.2 kg (114.8 pounds)
Adverse reactions / side effects: Phlebitis, Muscle Atrophy, Pain, Post Procedural Complication, Condition Aggravated, Appendicitis Perforated, Gangrene, Collapse of Lung, Haematotoxicity, Peritonitis, Complex Regional Pain Syndrome, Joint Sprain, Pleural Effusion
Adverse event resulted in: life threatening event, hospitalization
Suspect drug(s):
Lotrel
Dosage: 1 tab daily po
Administration route: Oral
Indication: Hypertension
Start date: 2001-01-01
End date: 2007-02-20
MS Contin
Dosage: 1 tablet twice daily-bid- po
Administration route: Oral
Indication: Complex Regional Pain Syndrome
Start date: 2000-08-20
End date: 2007-02-20
Adverse event in 52 year old female receiving MS Contin (Morphine)
Reported by a individual with unspecified qualification on 2007-01-18
Patient: 52 year old female, weighing 63.0 kg (138.6 pounds)
Adverse reactions / side effects: Weight Decreased, Asthma, Abdominal Pain, Pyrexia, Loss of Consciousness, Pneumonia, Drug Abuser, Drug Withdrawal Syndrome, Delirium, Tremor, Paraesthesia, Dehydration, Anorexia, Disturbance in Attention, Vision Blurred, Pain, Disorientation, Somnolence, Speech Disorder, Myalgia, RED Blood Cell Count Decreased, Injection Site Reaction, Dizziness, Depression, Vomiting, Nausea, Dental Caries, Blood Potassium Decreased, Diarrhoea, Alopecia, Bronchitis, Memory Impairment, Asthenia
Adverse event resulted in: hospitalization
Suspect drug(s):
MS Contin
Dosage: unk, unk
Indication: Drug USE FOR Unknown Indication
Start date: 2005-09-25
PEG-Intron
Dosage: unk, unk
Indication: Hepatitis C
Start date: 2005-09-25
Ribasphere
Dosage: unk, unk
Indication: Hepatitis C
Start date: 2005-09-25
Other drugs received by patient: Aspirin; Buspar; Calcium; Glucosamine W / Chondroitin Sulfates; Hydromorphone HCL; Lecithin; Levothyroxine Sodium; Vitamin CAP; Omega-3; Promethazine; Vitamin A+D; Vitamin B Complex CAP; Ascorbic Acid; Vitamin E; Wellbutrin; Albuterol Sulate; Flaxseed OIL; Inderal; Epogen; Iron
Adverse event in 52 year old female receiving MS Contin (Morphine)
Reported by a individual with unspecified qualification from United States on 2007-01-16
Patient: 52 year old female, weighing 63.0 kg (138.6 pounds)
Adverse reactions / side effects: Weight Decreased, Abdominal Pain, Asthma, Pyrexia, Loss of Consciousness, Injection Site Erythema, Pneumonia, Drug Abuser, Injection Site Bruising, Drug Withdrawal Syndrome, Delirium, Tremor, Paraesthesia, Respiratory Tract Congestion, Anorexia, Dehydration, Vision Blurred, Disturbance in Attention, Pain, Injection Site Swelling, Disorientation, Somnolence, Speech Disorder, Myalgia, RED Blood Cell Count Decreased, Injection Site Reaction, Dizziness, Depression, Vomiting, Nausea, Dental Caries, Burning Sensation, Diarrhoea, Blood Potassium Decreased, Alopecia, Bronchitis, Memory Impairment, Asthenia
Adverse event resulted in: hospitalization
Suspect drug(s):
MS Contin
Dosage: unk, unk
Indication: Drug USE FOR Unknown Indication
End date: 2005-10-01
MS Contin
Start date: 2005-01-01
MS Contin
End date: 2005-09-25
PEG-Intron
Dosage: unk, unk
Indication: Hepatitis C
Start date: 2005-09-25
Ribasphere
Administration route: Oral
Indication: Hepatitis C
Start date: 2005-09-25
Other drugs received by patient: Aspirin; Buspar; Calcium; Glucosamine W / Chondroitin Sulfates; Hydromorphone HCL; Inderal; Lecithin; Levothyroxine Sodium; Morphine Sulfate; Vitamin CAP; Omega-3; Promethazine; Vitamin A and D; Vitamin B Complex CAP; Ascorbic Acid; Vitamin E; Wellbutrin; Morphine Sulfate; Flaxseed OIL; Calcium; Albuterol; Epogen; Iron; Inderal; Doxycycline Hydrochloride
|
